Background: Hematologic markers, such as the neutrophil-to-lymphocyte ratio (NLR), characterize the inflammatory response to cancer and are associated with poorer survival in various malignancies. We evaluate the effect of pretreatment NLR on overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC).
| I NT ROD UCTI ON
Head and neck squamous cell carcinoma (HNSCC) represents a variety of malignant diseases of the upper aerodigestive tract. Etiologic factors have been identified, such as tobacco, alcohol, viral agents, genetic factors, radiation, occupational exposure, and immunodeficiency. 1, 2 The increasingly recognized interaction between the host's immune system and cancer cells has led to understanding in tumor surveillance, progression, and metastasis. 3 Hematologic markers, such as neutrophil, lymphocyte, monocyte, and platelet counts, have demonstrated a relationship to adverse clinical outcomes. 4 As tumors develop, invade, and metastasize, inflammatory factors play an important role in the malignant microenvironment. 5 Within recent years, new data have been published emphasizing the role of neutrophils and their ability to acquire tumor-promoting activity, including angiogenesis, mutagenesis, and immunosuppression. 6 More specifically, multiple authors have confirmed that an elevated neutrophil-to-lymphocyte ratio (NLR) was shown to be an independent prognostic factor in patients with esophageal, gastric, colon, liver, prostate, and gallbladder cancers. 4, [7] [8] [9] [10] [11] Therapeutic options for HNSCC are based on tumor staging, performance status, and related functional and physical comorbidities. Despite this, predicting response to treatment, local recurrence, distant metastasis, and survival remain a challenge. 12 Several authors have shown a relationship between pretreatment NLR and overall survival (OS) in patients with HNSCC (Table 1 ). A need to explore parameters to predict outcome and identify patients at heightened risk of treatment failure or poor survival is essential and can potentially guide new therapeutic strategies. To our knowledge, this is the first meta-analysis studying the impact of the NLR biomarker in patients with HNSCC. The NLR is a simple, inexpensive, and widely available test, making it a potential candidate prognostic factor to supplement tumor staging and personalizing care.
| MA TERI A LS AND M ETH ODS

| Search strategy
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 guidelines, a systematic search was conducted of MEDLINE, EMBASE, PubMed, Web of Science, and Cochrane electronic databases from 1980 to January 2017. The search strategy consisted of "neutrophil, lymphocyte, neutrophil to lymphocyte OR NLR" AND "head and neck neoplasms" AND "prognosis OR survival" for articles published up to and including January 2017. Eligible articles included those of patients with a new diagnosis of HNSCC (oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx, excluding salivary glands and hematologic malignancies) with reported pretreatment NLR, NLR cutoff values, and relationship between NLR and OS. Articles were excluded if they were case reports, abstracts, presentations, editorials, perspectives, reviews, or expert opinions. In addition, articles with no available English translation or insufficient data to estimate hazard ratios were excluded. The systematic search was facilitated by the help of a medical librarian. The study was exempted from the institutional ethics board given the nature of the research (MUHC 2018-3761).
| Data extraction and outcomes
A total of 241 potential articles were identified using the keywords mentioned above. Individual abstracts were screened to select the studies that followed the criteria for this metaanalysis. Full texts of selected articles were then retrieved and rescreened for possible inclusion in the current meta-analysis by 2 different observers independently. Data extracted from these studies included: authorship, publication year, country, sample size, tumor site and stage, NLR, NLR cutoff value, treatment, and hazard ratio for OS with associated confidence intervals (CIs). The NLR was calculated from pretreatment blood testing. Given the variability of cutoffs in the NLR reported, dichotomous reporting (high or low NLR) was used for analysis. The OS was defined as survival time in months since treatment. Abbreviations: chemo, chemotherapy; CI, confidence interval; CRT, chemoradiotherapy; HP, hypopharynx; L, larynx; NAC, neoadjuvant chemotherapy; NLR, neutrophil-to-lymphocyte ratio; NP, nasopharynx; OC, oral cavity; OP, oropharynx; PORT, postoperative radiotherapy; Tx, treatment; XRT, external radiotherapy; NAC, neoadjuvant chemotherapy.
| Statistical analysis
The meta-analysis was undertaken using Review Manager (RevMan version 5.3; Copenhagen, Denmark). 37 An inverse variance, random-effects model evaluating the hazard ratio for OS of pretreatment NLR was used to analyze the data. Heterogeneity was assessed using I 2 statistics. In addition, subgroup analysis on tumor site was undertaken based on available data. Reporting, publication, and bias were assessed using a funnel plot.
| R ES ULT S
Searching the databases screened a total of 241 studies. From these, 199 articles were excluded at the abstract level because they were either animal studies, duplicates, or nonrelevant to the clinical question ( Figure 1) . Full-text of 29 publications were recovered, and then 5 of them were excluded, because it was not possible to extract complete data (such as OS, NLR cutoff, or hazard ratio). The remaining 24 studies consisting of 6479 patients were included for the metaanalysis. A summary of these 24 studies is presented in Table 1 . Most retained articles consisted of retrospective observational studies; patients with HNSCC at different sites were included in the majority of studies. In select articles, the authors described the association between NLR and OS based on a single site, most often being the larynx or oral cavity. Patient size per article ranged from 46 to 1410 patients. The range of the NLR used in the analyzed articles was from 2.04 to 5. The cutoff NLR was established in the majority of articles using a receiver operator characteristics curve or median values of their respective cohort. The combined hazard ratio for OS of patients with HNSCC with an elevated NLR was 1.78 (95% CI 1.53-2.07; P < .001), I 2 66%; P < .001; Figure 2 13-36
. A Funnel plot to examine publication bias is illustrated in Figure 3 . The plot shows the existence of possible reporting bias as data points appear asymmetric. The pooled hazard ratios for NLR on OS: in the oral cavity 1.56, 95% CI 1. specific hazard ratios consistently show a worse OS in patients with an elevated NLR (Figures 4-7 ).
| D IS C US S I ON
An elevated NLR has been showed to be strongly associated with decreased survival in patients with HNSCC. This information is consistently presented in the literature across different HNSCC sites, such as the oral cavity, nasopharynx, oropharynx, larynx, and hypopharynx. Our study is the first meta-analysis studying the impact of the NLR biomarker in HNSCC prognosis. The development and progression of malignant cells is known to be a multifactorial process involving host-tumor interactions. 3, 38 Bidirectional communication between cells and their microenvironment is critical. Interactions between tumor cells and the associated stroma represent a powerful relationship that influences disease initiation, progression, and patient prognosis. 39 The link between inflammation and carcinogenesis was first proposed by Rudolf Virchow in 1863, after the observation that infiltrating leukocytes were a hallmark of tumors. Since then, several studies have contributed to the characterization of the microenvironment in order to understand and treat cancer. Although cancer had previously been viewed as a heterogeneous disease involving aberrant mutations in tumor cells, it is now evident that tumors are also diverse by nature of their microenvironmental composition, and stromal cell proportions or activation states. 39 In response to the environmental conditions and oncogenic signals from growing tumors, the microenvironment continually changes over the course of tumor progression having influences on the metastatic process. Tumor cells can drive the construction of their own niche. 39 An elevated NLR identifies a systematic inflammatory response. 4 Guthrie et al 38 showed that cancer-associated inflammation was a key determinant to clinical outcomes. Particularly, patients with early postoperative infections after ablative surgery were at an increased risk for adverse longterm outcomes related to tumor spread. 40 Various authors have shown that cancer cells recruit and activate leukocytes; a proposed pathophysiologic mechanism to explain poorer outcomes in such patients is the systemic activation of neutrophil extracellular traps (NETs). 3, 40 The NETs are extracellular DNA aggregates associated with cytotoxic enzymes produced by neutrophils to capture and destroy microorganisms. 3 Experimentally induced systemic bacterial infection significantly contributes to metastatic tumor seeding to the liver and lung tissue through increased adhesions from the NETs. 40 In a similar fashion, cancer cells can induce widespread NET formation leading to enhanced adhesion and metastasis in those with elevated NLRs. 3, 4 The precise role of neutrophils within the tumor microenvironment remains controversial. [41] [42] [43] On the one hand, tumor-associated neutrophils (TANs) appear to contribute toward tumor growth, angiogenesis, and immune tolerance. 41, 42 A crosstalk between immune and tumor cells within the microenvironment allows for immunoediting, whereby tumor cells mediate growth factor and immune tolerance through TAN. 42 Furthermore, tumor cells have been shown to secrete cytokines, attracting neutrophils, and contributing to the destruction of basement membranes and invasion into surrounding tissues. 43 Factors, such as tumorderived macrophage migration inhibitory factors, stimulate TAN to release proteases in the tumor microenvironment facilitating invasion and nodal metastasis. 43 On the other hand, neutrophils are necessary for effective recruitment of T cells and the associated cytotoxic effects on tumors as in its role in nonmuscle invasive bladder cancer using Bacillus Calmette-Guerin immunotherapy. 44 The inhibition of TAN by blockage of CXCL8/interleukin-8 receptors has been shown to decrease tumor burden. 45 Such antineutrophil immunotherapies, which target the CXCL-8/CXCR axis, have shown promise in murine models in which lung cancer tumor burden and TAN greatly reduced after CXCR2 inhibitors. 45, 46 Neutrophils seem to have a response with targeted monoclonal antibody therapy. 46 They function as effector cells in both complement-dependent cascade, regulation of the adaptive immune system, and antibody-dependent cellmediated cytotoxicity tumor elimination. 46 No study on patients with HNSCC has shown decreased effect of NLR after immunotherapy. Several biases may limit the reproducibility and generalizability of results. Of note, the I 2 for all HNSCC sites pooled was 66% with a funnel plot indicating evidence of high heterogeneity. This may be due to multiple factors. Figure 3 demonstrates an asymmetric funnel plot; the possibility of unpublished data cannot be excluded. That being said, multiple medical database libraries were queried. The published studies included a variety of primary sites (such as the oropharynx, hypopharynx, larynx, and oral cavity) each with distinct tumor-related biology and treatments protocols. A notable example is the hypopharynx cancer subgroup in which a hazard ratio of 2.36 was identified. In addition, tumor staging varied; no subgroup analysis could be performed given the limited data. The granularity of the data did not allow for complete subgroup analysis regarding primary treatment modality and human papillomavirus status. Additionally, no consistent NLR cutoff was used across all studies (cutoff ranged from 2.04-5). Most articles included NLR cutoff values based on median NLR scores, receiver-operator characteristic curves, or referred to previous literature of other solid organ tumors. Despite this, the evidence is clear that an elevated NLR is associated with decreased patient's survival probability independently of the tumor location. An additional confounder to the NLR can be in patients with comorbid cardiovascular disease, chronic inflammatory states, and medications that can all alter this ratio. An elevated NLR in patients with HNSCC indicates poorer overall outcome and can potentially impact treatment. Such patients may benefit from earlier, systemic treatment; however, evidence is lacking in the literature. That being said, additional prognostic markers are needed to better define a patient with HNSCC given clinical course and to personalize the care.
| CON CLU S IO N
Patients with HNSCC with an elevated pretreatment NLR are more likely to have a decreased OS. The NLR provides a simple and robust prognostic factor in the care of patients with head and neck cancer. Further studies are required to characterize the role of the NLR in HNSCC and ascertain if a causal link exists.
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